Pharma psychiatry
SSRIs, SNRIs, atypicals, novel mechanisms. The pipeline, the labels, the reimbursement.
First reporting in this vertical publishes this week.
In the pipeline
| Program | Sponsor | Phase | Status |
|---|---|---|---|
| Cobenfy (xanomeline-trospium) Schizophrenia | Bristol Myers Squibb | Approved | Adjunctive MDD trials underway |
| AXS-05 (Auvelity) Major depressive disorder | Axsome Therapeutics | Approved | Marketed; Alzheimer's agitation filed |
| Zuranolone (Zurzuvae) Postpartum depression | Sage Therapeutics / Biogen | Approved | Marketed for PPD; MDD rejected |
| Navacaprant (NMRA-140) Major depressive disorder | Neumora Therapeutics | Phase 3 | KOAST program enrolling |
| Esketamine (Spravato) Treatment-resistant depression | Johnson & Johnson | Approved | Monotherapy label cleared |
Recent filings
DEA